Cetuximab off-label useAcquired resistance: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1853卷 / 1期

关键词：

D O I：

10.1007/s40278-021-94989-0

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：123 / 123

相关论文

共 50 条

[1] Cetuximab/encorafenibDevelopment of drug resistance and off-label use: case report
[J]. Reactions Weekly, 2022, 1894 (1) : 103 - 103
[2] CetuximabAseptic meningitis following off-label use of cetuximab: case report
[J]. Reactions Weekly, 2018, 1729 (1) : 72 - 72
[3] DexamethasoneInsulin resistance and off-label use: case report
[J]. Reactions Weekly, 2022, 1911 (1) : 173 - 173
[4] BamlanivimabAcquired resistance and off-label use: case report
[J]. Reactions Weekly, 2023, 1938 (1) : 302 - 302
[5] Cetuximab/cisplatin/gemcitabineLeukocytopenia and thrombocytopenia following off-label use: case report
[J]. Reactions Weekly, 2022, 1917 (1) : 168 - 168
[6] NivolumabDrug resistance following off-label therapy: case report
[J]. Reactions Weekly, 2020, 1808 (1) : 228 - 228
[7] Inotuzumab ozogamicinDevelopment of resistance and off-label use: case report
[J]. Reactions Weekly, 2019, 1783 (1) : 147 - 147
[8] DalbavancinDrug-resistance and off-label use: case report
[J]. Reactions Weekly, 2019, 1734 (1) : 170 - 170
[9] Azacitidine/olaparibDrug resistance and off-label use: case report
[J]. Reactions Weekly, 2022, 1904 (1) : 92 - 92
[10] Ixazomib/venetoclaxDrug resistance and off-label use: case report
[J]. Reactions Weekly, 2022, 1927 (1) : 308 - 308

← 1 2 3 4 5 →